Press Releases & Announcements

SOLICITATION FOR ACTG SCIENCE COMMITTEE MEMBERSHIP POSITIONS DUE SEPTEMBER 21ST

Aug 26, 2022

UPCOMING MONKEYPOX STUDY

Aug 22, 2022

ACTG ANNOUNCES LAUNCH OF ACTIV-2D, A GLOBAL PHASE 3 TRIAL OF THE NOVEL INVESTIGATIONAL COVID-19 ORAL ANTIVIRAL AGENT S‑217622

Aug 15, 2022

ACTG ANNOUNCES PUBLICATION OF #ACTIV-2 STUDY IN CELL REPORTS MEDICINE DEMONSTRATING RAPID CLEARANCE OF CULTURABLE SARS-COV-2 FOLLOWING MONOCLONAL ANTIBODY TREATMENT

Jul 27, 2022

ACTG LAUNCHES A5383, CLINICAL TRIAL EVALUATING POTENTIAL IMMUNOLOGIC BENEFITS OF TREATING ASYMPTOMATIC CMV IN PEOPLE LIVING WITH HIV

Apr 22, 2022

REQUEST FOR APPLICATIONS SMALL CLINICAL TRIALS ADVANCING HIV REMISSION AND CURE- DUE APRIL 1, 2022

Mar 28, 2022

ACTG AND SHIONOGI ANNOUNCE PROGRESS ON GLOBAL PHASE 3 TRIAL OF NOVEL COVID-19 ORAL ANTIVIRAL AGENT S 217622

Mar 16, 2022

ACTG TO MAKE 33 PRESENTATIONS AT CROI 2022

Feb 08, 2022

ACTG ANNOUNCES INITIATION OF A5355, CLINICAL TRIAL STUDYING NEW CMV VACCINE

Dec 16, 2021

SCOTT HAMMER

Dec 07, 2021

POORER MUSCLE QUALITY AND QUANTITY WITH ART INITIATION IS ASSOCIATED WITH GREATER INFLAMMATION AND IMMUNE ACTIVATION

Dec 01, 2021

ACTG ANNOUNCES INITIATION OF CLO-FAST, ITS FIRST TRIAL EVALUATING A THREE-MONTH TB TREATMENT

Nov 10, 2021